title: Statin use and the risk of recurrence after radical prostatectomy in a cohort of men with inherited and/or early-onset forms of prostate cancer.
abstract: OBJECTIVE
  To investigate whether the use of statin medications is associated with a reduced risk of biochemical recurrence (BCR) in men with inherited and/or early-onset prostate cancer who have been treated with radical retropubic prostatectomy (RRP).
  
  
  METHODS
  Study patients are men with inherited and/or early-onset prostate cancer enrolled in the University of Michigan Prostate Cancer Genetics Project. Men enrolled in Prostate Cancer Genetics Project were surveyed to determine statin medication use history from 1999 to 2009. Diagnosis and treatment data were taken from medical records. BCR was defined as a single increase in prostate-specific antigen level to ≥0.4 ng/mL after treatment with RRP. Statin use was modeled as a time-dependent variable, and BCR after RRP was both examined using crude Cox proportional hazards models and adjusted for known clinical prognostic factors.
  
  
  RESULTS
  A total of 539 men treated with RRP were included in this study. Of these, 47.9% of men used statin medications, and 115 (21%) men experienced a recurrence. Ever-statin use was not associated with risk of recurrence in crude models (hazards ratio=1.04, 95% confidence interval=0.72-1.49, P value=.86) or in models adjusted for clinical characteristics (hazards ratio=1.06, 95% confidence interval=0.68-1.64, P value=.81). Furthermore, no association was observed when comparing men with high-Gleason grade cancers with those with low-Gleason grade cancers.
  
  
  CONCLUSIONS
  Statin use was not associated with a reduced risk of BCR after RRP in this study; however, these men at increased risk for prostate cancer represent a subgroup of men who may benefit from further study of statin medication use to slow or prevent BCR.
authors.affiliation: Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI. Electronic address: mshak@umich.edu.
authors.forename: Miriam B
authors.initials: MB
authors.lastname: Ishak-Howard
authors.affiliation: Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI.
authors.forename: Linda A
authors.initials: LA
authors.lastname: Okoth
authors.affiliation: Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI; Department of Urology, University of Michigan Medical School, Ann Arbor, MI.
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Cooney
mesh_terms: D000368:Aged; D015331:Cohort Studies; D016001:Confidence Intervals; D055088:Early Detection of Cancer; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000517:prevention & control*; D016016:Proportional Hazards Models; D011468:Prostatectomy / Q000009:adverse effects / Q000379:methods*; D011471:Prostatic Neoplasms / Q000473:pathology / Q000601:surgery*; D012016:Reference Values; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
references.citation: Integr Cancer Ther. 2012 Jun;11(2):83-9
references.pmid: 21821653
references.citation: Urology. 2009 Sep;74(3):643-7
references.pmid: 19501891
references.citation: Int J Cancer. 2008 Aug 15;123(4):899-904
references.pmid: 18491405
references.citation: Urol Clin North Am. 2011 Aug;38(3):243-59
references.pmid: 21798387
references.citation: Cancer. 2010 Jul 15;116(14):3389-98
references.pmid: 20586112
references.citation: J Urol. 2009 Dec;182(6):2702-7
references.pmid: 19836772
references.citation: Urology. 2010 Nov;76(5):1240-4
references.pmid: 20627287
references.citation: BJU Int. 2011 Oct;108(8 Pt 2):E211-6
references.pmid: 21453350
references.citation: J Clin Oncol. 2004 Feb 1;22(3):439-45
references.pmid: 14691120
references.citation: BJU Int. 2013 Mar;111(3 Pt B):E71-7
references.pmid: 23017100
references.citation: Ann Pharmacother. 2008 Sep;42(9):1208-15
references.pmid: 18648016
references.citation: Ann Oncol. 2013 Jun;24(6):1427-34
references.pmid: 23508824
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):88-94
references.pmid: 18199714
references.citation: Mol Cancer Ther. 2006 Sep;5(9):2310-6
references.pmid: 16985065
references.citation: J Exp Clin Cancer Res. 2005 Mar;24(1):55-61
references.pmid: 15943032
references.citation: Cancer Causes Control. 2010 Jan;21(1):61-8
references.pmid: 19806465
references.citation: J Urol. 2001 Feb;165(2):469-73
references.pmid: 11176398
references.citation: Nat Rev Cancer. 2007 Apr;7(4):256-69
references.pmid: 17384581
references.citation: J Urol. 2010 Jan;183(1):118-24
references.pmid: 19913252
references.citation: Urology. 2004 Feb;63(2):282-7
references.pmid: 14972472
references.citation: J Clin Oncol. 2010 Jun 1;28(16):2653-9
references.pmid: 20421534
references.citation: J Urol. 2004 Sep;172(3):910-4
references.pmid: 15310996
references.citation: Cancer. 2012 Aug 15;118(16):4046-52
references.pmid: 22180145
references.citation: Int J Cancer. 2010 Oct 1;127(7):1650-9
references.pmid: 20073066